Dune Medical scores $12M to take MarginProbe beyond breast cancer

MarginProbe uses radiofrequency spectroscopy to detect residual cancer cells during a lumpectomy, so the surgeon may remove them and avoid a second procedure. (Dune Medical)

Dune Medical, which markets a tool that spots residual breast cancer cells following a lumpectomy, has raised $12.3 million. The funds will drive the development of the company’s technology for other types of cancer.

Breast cancer patients may undergo a mastectomy—removal of the whole breast—or a lumpectomy, which only removes the part of the breast containing the tumor. The goal of a lumpectomy is to get rid of the tumor, as well as some of the breast tissue around it. But sometimes, cancerous cells are left behind, which can necessitate a second procedure.

Dune Medical’s MarginProbe uses radiofrequency spectroscopy to identify cancerous tissue in real time. RF spectroscopy spots cancerous tissue by measuring the reflection of electromagnetic fields from the patient’s tissue. Healthy tissue and cancerous tissue have different electrical properties.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

MarginProbe is used during a lumpectomy procedure. If it turns up residual cancer cells, the surgeon may then remove more tissue while the patient is still under anesthesia.

RELATED: With MarginProbe on the market, Dune Medical sees bright future

Dune Medical is looking to apply its RF spectroscopy platform to other cancer types, including prostate, colon, lung and pancreatic cancers. The company scored a European Commission Horizon 2020 grant last summer to develop a “smart biopsy system” based on its RF spectroscopy tech.

“[The biopsy system] will provide radiologists and surgeons immediate graphic characterizations of tissue abnormalities along the tip of the biopsy needle, just before samples are taken,” said Dune Medical CEO Dan Hashimshony at the time. “This real-time insight can help reduce the time to a definite diagnosis and repeated biopsies.”

Suggested Articles

Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.

The FDA approved a new, tiny pacemaker from Medtronic that does not require the wiring of separate electrodes between the implant and the heart.

Antibiotics player Summit Therapeutics is gearing up for a new clinical trial of its lead asset, an antibiotic for Clostridium difficile infection.